🔬 This is Part 2 of the Breed-to-Bowl canine longevity series. The
overview covers all five topics at a high level.
Part 1 went deep on caloric restriction and once-daily feeding. This post goes deep on rapamycin — what it is, what the dog research actually shows, and where things stand with the TRIAD trial.
In 1972, a Canadian research team collected soil samples from the island of Rapa Nui — Easter Island — as part of a scientific expedition. One of those samples contained a bacterium called Streptomyces hygroscopicus, and that bacterium produced a compound nobody had seen before. They named it after where they found it. Rapamycin.
For the next few decades, rapamycin was primarily known as an immunosuppressant, used to prevent organ rejection in transplant patients. At high doses, it dials down the immune system significantly. That is still how most doctors think about it. But in the last 15 years, something has shifted. At much lower doses, rapamycin does something quite different. And what it does at those lower doses has put it at the centre of some of the most serious aging research in the world — including the largest clinical longevity trial ever conducted in dogs.
That trial is running right now.
The Biology Worth Understanding
Before getting into the dog data, it is worth spending a few minutes on the underlying mechanism. Not because the science is complicated, but because understanding it is what makes the research compelling rather than sounding like just another longevity supplement claim.
Every cell in your dog's body contains a protein complex called mTOR — mechanistic Target Of Rapamycin. Think of it as a cellular accelerator. When mTOR is active, cells go into growth and production mode: making proteins, dividing, expanding. This is useful in youth and recovery. The problem is that mTOR has no built-in awareness of age. In middle-aged and older animals, it tends to stay chronically active, and the downstream effects of that are part of what we call aging.
When mTOR runs too hot for too long, two things happen that matter enormously. First, a process called autophagy gets suppressed. Autophagy is the cell's internal cleaning system — it breaks down and recycles damaged proteins and worn-out organelles. Without it running properly, cellular debris accumulates, and cells lose efficiency. Second, the body's inflammatory load increases. Chronic low-grade inflammation, which rises with age in nearly every species studied, is now understood to be a driver of almost every major age-related disease: heart disease, cancer, neurodegeneration, arthritis.
Rapamycin, at low doses, puts a partial brake on mTOR. Not switching it off entirely, just slowing it down enough to shift the cellular balance from growth toward maintenance and repair. Autophagy runs more robustly. Inflammation is reduced. Cells behave more like younger cells.
The connection to Part 1 — caloric restriction
If you read the caloric restriction deep dive, this will sound familiar. Keeping a dog lean and, in particular, feeding once daily also acts on mTOR. When the body is in a mild caloric deficit — or even just in an extended fasting window overnight — mTOR activity naturally decreases and autophagy increases. This is a large part of why the once-daily feeding data from 24,000 dogs showed benefits across multiple organ systems.
Rapamycin is, in a sense, a pharmacological version of what caloric restriction does through diet. It mimics the cellular environment of a lean, fasting animal. Which is one reason researchers are interested in what the two interventions might achieve together — and why both are being studied through the same project, the Dog Aging Project.
What Happened in Mice (And Why It Matters for Dogs)
The reason rapamycin landed on researchers' radar for dogs was the mouse data. In 2009, a large National Institute on Aging study published in Nature showed that rapamycin extended median lifespan in mice by 9% in males and 14% in females. The result attracted attention for a specific reason: the treatment was started at 600 days of age, the equivalent of roughly 60 years in a human. An intervention that produced meaningful lifespan extension starting in middle age was not what most people expected.
Subsequent mouse studies pushed this further, showing improvements in cardiac function, immune function, cognitive performance, and cancer rates — not just raw lifespan numbers. The compound appeared to be producing broad healthspan benefits, not just adding time to the end of a life. That is a meaningful distinction.
Dogs were the obvious next candidate. They are companion animals with shorter lifespans than humans, they share our environments and many of our disease patterns, and they age fast enough that researchers could get answers within years rather than decades. In 2014, a team at the University of Washington led by Dr Matt Kaeberlein launched the first serious rapamycin trials in companion dogs.
The Dog Evidence: What the Studies Actually Showed
In 2017, Kaeberlein's team published the results of a randomised controlled trial in 24 middle-aged companion dogs. The dogs received either rapamycin or a placebo for 10 weeks at doses considerably lower than transplant immunosuppressive levels. The primary outcome they measured was cardiac function — because age-related decline in heart muscle performance is one of the clearest early indicators of biological aging across mammals.
Rapamycin significantly improved both systolic and diastolic heart function in the treated dogs compared to placebo. No clinical side effects were observed during the trial period. It was a small study, 10 weeks is short, and the researchers were clear that they could not yet make claims about lifespan. But the cardiac signal was clean, and it was consistent with what had been seen in mice.
26.8%
of owners in rapamycin group reported positive health changes
8.1%
reported positive changes in the placebo group
17
healthy dogs in the 2023 cardiac safety trial — all well-tolerated
A second trial published in 2023 followed 17 healthy client-owned dogs with low-dose rapamycin in a masked, placebo-controlled design specifically assessing both cardiac effects and safety. It confirmed the cardiac function improvements from the earlier study and found the drug well-tolerated across the group. One case report from the same period documented a Labrador Retriever who developed significantly elevated blood triglycerides after six months on low-dose rapamycin — an important finding that reinforced why routine blood monitoring matters when using this drug.
The owner-reported data is also notable. Across earlier Dog Aging Project rapamycin work, 26.8% of owners whose dogs received rapamycin reported positive changes in behavior or health, compared to 8.1% in the placebo group. These are subjective reports and should be interpreted cautiously. But the gap is large enough that it suggests something real is happening from the perspective of people who know their dogs well.
The TRIAD Trial: The Big Test
Everything before the TRIAD trial was preliminary. Important, encouraging, and scientifically credible — but small, short, and not designed to answer the question that actually matters: does rapamycin extend healthy lifespan in dogs?
The Test of Rapamycin In Aging Dogs (TRIAD) is the answer to that question. Led by researchers at Texas A&M University as part of the Dog Aging Project, and funded by a $7 million NIH grant awarded in early 2025, TRIAD is the first properly powered, randomised, placebo-controlled, multicenter clinical trial of any pharmacological intervention against biological aging to be conducted outside a laboratory, in any species.
That is not a small claim. It means dogs are the first non-laboratory animals to be enrolled in a rigorously designed trial whose explicit endpoints are lifespan and healthspan. The human longevity field is watching this closely.
🔬 TRIAD Trial: Key Facts
The Test of Rapamycin In Aging Dogs is the largest and most rigorous longevity drug trial ever conducted in companion animals.
Target Enrollment580 healthy dogs aged 7 and older
Trial DesignDouble-masked, randomized, placebo-controlled, multicenter
Sites20 veterinary sites across multiple countries
Funding$7 million from the US National Institutes of Health
Trial Duration3 years per enrolled dog
Status (mid-2026)Enrollment targeted complete late 2025; dogs in active treatment phase
The endpoints are not just "did the dog live longer." TRIAD is measuring cardiac function, mobility, cognitive performance, cancer incidence, and a range of other healthspan metrics alongside raw lifespan. This is significant because longevity research that only counts years misses the point. Adding two years of decline to a dog's life would be a failure. Adding two years of genuine health would be a genuine advance.
Full results from TRIAD are years away. The trial runs for three years per dog, and lifespan data by definition takes time. What we have right now is a well-designed trial, running, with promising preliminary data behind it. This is not a supplement marketed on hope. It is a serious scientific test of a serious hypothesis.
The Safety Picture — Being Honest About It
The most important distinction when thinking about rapamycin safety is dose. The doses used in longevity research in dogs are substantially lower than those used in human transplant patients. In transplant medicine, the goal is to suppress the immune system significantly enough to prevent organ rejection. That comes with real side effects: increased infection risk, wound healing problems, metabolic changes. The longevity doses are not trying to do that. They are trying to modulate mTOR gently, not switch it off.
⚠️ What the safety data actually shows
Generally well-tolerated: Both the 2017 (24-dog) and 2023 (17-dog) trials found rapamycin well-tolerated at longevity doses, with no severe adverse events during the trial periods.
Hypertriglyceridemia: One published case report documented a Labrador who developed severely elevated blood fats after six months on low-dose rapamycin. The dog was asymptomatic but the finding underscores the need for routine blood work monitoring — ideally a full metabolic panel every 3 to 6 months.
Other reported events: In earlier studies, individual dogs in rapamycin groups experienced reduced exercise willingness, a skin infection, and one mast cell tumor diagnosis. Whether these were related to the drug or coincidental is unclear. Mast cell tumors are common in middle-aged dogs regardless.
Immune effects at longevity doses: The longevity doses used in dog trials are not designed to be immunosuppressive. However, because rapamycin does have immune-modulating properties at any dose, dogs with active infections, autoimmune conditions, or scheduled vaccinations need specific discussion with a vet before starting.
The honest summary is that the short-term safety data looks reasonably good at longevity doses, but long-term data is still being generated through TRIAD. Anyone who tells you rapamycin is definitively safe long-term in dogs is getting ahead of what the evidence currently shows. Anyone who tells you it is dangerous at longevity doses is equally getting ahead of what the evidence shows. We are in the middle of finding out.
Who Is This Most Relevant For Right Now?
TRIAD enrolled dogs aged 7 and older. This is not arbitrary. Seven years is roughly the point at which most medium and large breeds have crossed into biological middle age. The cellular changes that rapamycin appears to address — accumulated inflammation, declining autophagy, cardiac drift — become measurable around this point and compound from there.
Giant breeds are in a different category. A Great Dane, Irish Wolfhound, or Saint Bernard at 6 is already in senior territory. Their biology ages on a faster clock, they have the shortest lifespans of any dogs, and they are often the ones with the most to gain from interventions that target the aging process itself rather than specific diseases.
Rapamycin is not currently relevant for puppies, young adult dogs, or dogs with active infections, kidney disease, or upcoming vaccinations. The longevity research is focused on healthy middle-aged and older dogs — dogs who are well now, and whose owners want to keep them that way for longer.
Small breeds are interesting. They naturally live longer than large breeds, are less represented in the longevity research, and have fewer of the cardiovascular markers that rapamycin appeared to improve in the Kaeberlein trials. The case for small breeds is less clear, though the underlying mTOR biology presumably applies. This is an area where the science genuinely has not caught up yet.
How to Have the Conversation With Your Vet
Most general practice vets are not currently familiar with rapamycin in the longevity context. They may know it as a transplant drug. They may have heard the name but not read the dog studies. This is not a criticism — the research is relatively recent and moving fast. But it means the conversation requires some preparation on your end.
The most useful thing you can bring is the published research. The 2023 cardiac safety trial is freely available on PubMed (search "rapamycin dogs cardiac function 2023"). The TRIAD trial design paper was published in PMC. Having those in hand signals that you have done your homework and are not asking for a trendy supplement — you are asking about a drug with peer-reviewed data behind it.
Vets who follow geroscience literature, integrative vets, and veterinary internists at university teaching hospitals are generally better starting points than general practice. If your vet is open to exploring it, rapamycin requires a prescription, and the longevity doses used in research are compounded by veterinary compounding pharmacies in a format appropriate for dogs. Commercial human-approved sirolimus tablets (rapamycin's generic name) are also available, but dosing needs careful calibration to the dog's weight — this is not something to approximate.
Routine blood monitoring before starting and every 3 to 6 months while using it is the standard approach in research settings. A full metabolic panel that includes triglycerides is the minimum. This is non-negotiable.
The Honest Picture
Where rapamycin actually stands as of mid-2026
Rapamycin has extended lifespan in yeast, worms, flies, and mice. It has improved cardiac function in two randomised controlled dog trials. It produces a biological state that closely mirrors what caloric restriction does through diet. The TRIAD trial — the first properly designed lifespan trial of any drug in companion animals — is running now, with results years away.
What we do not have yet is a definitive answer about whether rapamycin extends healthy lifespan in dogs. TRIAD will provide that answer. Until it does, the honest position is: the science is more serious than almost any other longevity intervention you will encounter, but it is not yet conclusive for the endpoint that matters most.
For dogs who are already 7 or older, particularly large or giant breeds, the risk-benefit conversation is a reasonable one to have with the right vet. The preliminary safety profile at low doses is acceptable and the mechanistic logic is sound. For younger dogs, the current evidence does not support early intervention. Caloric restriction — covered in Part 1 — remains the most proven, most accessible, and most immediately actionable intervention available.
The two are not mutually exclusive. In fact, the biology suggests they may work well together.
Next in the series
Part 3: Loyal's LOY Drugs — The First Purpose-Built Canine Longevity Pharmaceuticals
A San Francisco startup has developed the world's first drugs specifically designed to extend dog lifespan. One is already in an FDA review pathway. Here is what LOY-001, LOY-002, and LOY-003 actually target — and what FDA approval would mean in practice.
